Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）

Inclusion Criteria:

• Signed and dated informed consent

• Age：18~75 years;

• Subjects with histologically or cytologically confirmed locally advanced and/oradvanced NSCLC

• at least two systematic chemotherapy with upwards of 1-line treatments or cannotsuffer

• The negative patients in EGFR&ALK can participate or who positive in EGFR&ALK, have orhave not drug tolerance after the treatment with relative targeted drugs

• Subjects with at least one measurable lesion as defined by RECIST (version 1.1)

• Expected Survival Time: Over 3 months

• ECOG PS：0-1,

• main organs function is normal

• The woman patients of childbearing age who must agree to take contraceptive methods (e.g. intrauterine device, contraceptive pill or condom) during the research andwithin another 6 months after it; who are not in the lactation period and examined asnegative in blood serum test or urine pregnancy test within 7 days before theresearch; The man patients who must agree to take contraceptive methods during theresearch and within another 6 months after it

Exclusion Criteria:

• 1.Small Cell Lung Cancer (including small cell cancer and other kinds of cancer mixedwith non-small cell cancer)

• lung squamous carcinoma

• Other active malignancies requiring treatment

• History of malignancy

• Have got non remissive toxic reactions derived from previous therapies, which is overlevel 1 in CTC AE (4.0), alopecia NOT included

• Abnormal coagulation (INR＞1.5 or PT＞ULN+4s or APTT >1.5 ULN); Patients with anyphysical signs of bleeding diathesis or receiving thrombolysis and anticoagulation

• take major surgical treatments or have serious trauma before grouping, or the impactof surgery or trauma has been eliminated for less than 14 days.

• Patients with active or unable to control serious infections;

• Patients with Grade II or higher myocardial ischemia, myocardial infarction ormalignant arrhythmias(including QTc male ≥ 450 ms, female ≥ 470 ms) ; Patients withgrade III to IV cardiac insufficiency, or left ventricular ejection fraction (LVEF) <50% (NYHA Classification)

• Patients with non-healing wounds or fractures

• with kinds of factors which affect oral medicine (e.g. failing to swallow,gastrointestinal tract getting resected, chronic diarrhea and ileus).

• get arterial/venous thrombosis within 12 months, such as cerebrovascular accidents (including temporary ischemic stoke), deevenous thrombosis, and pulmonary embolism

• plan to take systemic anti-tumor therapy within 4 weeks before grouping or during themedicine-taking period of this research, including Cytotoxic Therapy, SignalTransduction Inhibitor, and Immunotherapy

• Patients with cirrhosis, decompensated liver disease, or active hepatitis Havesuffered from hemorrhagic disease or coagulation dysfunction

• diagnosed with disease which will severely endanger the security of patients orinfluence the completion of this research